We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+39.2%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$505M
Cap. Flow
+$114M
Cap. Flow %
7.17%
Top 10 Hldgs %
57.57%
Holding
93
New
29
Increased
21
Reduced
9
Closed
17

Top Buys

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$33.8M
2
GILD icon
Gilead Sciences
GILD
+$30.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$26.9M
4
LLY icon
Eli Lilly
LLY
+$22.9M
5
ABBV icon
AbbVie
ABBV
+$17.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$27.6M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.6M
4
BIIB icon
Biogen
BIIB
+$16.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 91.07%
2 Miscellaneous 8.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
51
CALL
Pfizer
PFE
$158B
$5.72M 0.36%
+184,450
New +$6.27M
ITCI
52
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.65M 0.36%
+220,000
New +$4.45M
CCXI
53
DELISTED
ChemoCentryx, Inc.
CCXI
$5.58M 0.35%
96,916
+30,221
+45% +$1.64M
CALA
54
DELISTED
Calithera Biosciences, Inc
CALA
$5.49M 0.35%
52,020
+11,070
+27% +$1.31M
KALA icon
55
KALA BIO
KALA
$10.8M
$5.33M 0.34%
203
-243
-54% -$6.88M
QTTB icon
56
Q32 Bio
QTTB
$332M
$5.23M 0.33%
19,143
+6,328
+49% +$1.69M
CYTK icon
57
Cytokinetics
CYTK
$10.3B
$3.78M 0.24%
+160,217
New +$3M
ETTX
58
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$3.49M 0.22%
1,180,178
– –
MRSN
59
DELISTED
Mersana Therapeutics
MRSN
$3.23M 0.2%
5,519
-3,481
-39% -$1.19M
ACRS icon
60
Aclaris Therapeutics
ACRS
$818M
$3.1M 0.2%
1,911,573
– –
PTCT icon
61
CALL
PTC Therapeutics
PTCT
$5.64B
$3.04M 0.19%
60,000
+10,000
+20% +$491K
NVCR icon
62
CALL
NovoCure
NVCR
$1.82B
$2.96M 0.19%
+50,000
New +$3.29M
RETA
63
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.03M 0.13%
+13,035
New +$1.98M
APLS
64
DELISTED
Apellis Pharmaceuticals
APLS
$1.62M 0.1%
49,580
– –
CGEN icon
65
Compugen
CGEN
$235M
$1.56M 0.1%
103,587
-196,413
-65% -$2.65M
SNDX icon
66
Syndax Pharmaceuticals
SNDX
$1.77B
$1.36M 0.09%
+91,964
New +$1.4M
YARW
67
Yarrow Bioscience
YARW
$77.7M
$1.26M 0.08%
202
+34
+20% +$230K
NTLA icon
68
Intellia Therapeutics
NTLA
$1.71B
$1.21M 0.08%
+57,500
New +$977K
SYBX
69
DELISTED
Synlogic
SYBX
$1.17M 0.07%
38,331
– –
IMVT icon
70
Immunovant
IMVT
$8B
$987K 0.06%
+40,513
New +$868K
MRTX
71
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$922K 0.06%
+8,072
New +$783K
ARNA
72
DELISTED
Arena Pharmaceuticals Inc
ARNA
$877K 0.06%
+13,929
New +$766K
RIGL icon
73
Rigel Pharmaceuticals
RIGL
$882M
$622K 0.04%
33,970
-110,662
-77% -$1.99M
ORIC icon
74
Oric Pharmaceuticals
ORIC
$1.3B
$585K 0.04%
+17,369
New +$554K
PDSB icon
75
PDS Biotechnology
PDSB
$16.4M
$287K 0.02%
142,635
– –
1 2
3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2020 Portfolio in Review

As of Q2 2020, Sofinnova Investments held 93 positions worth $1.59B, up 47% from $1.08B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments deployed $114M of net new capital in Q2 2020, opening 29 new positions and adding to 21 existing holdings. Its largest new stake was Akouos Inc: 1,515,073 shares worth $34.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $17.6M trimmed.

  • Sofinnova Investments's largest Q2 2020 buy was Akouos Inc: 1,515,073 shares worth $34.1M.
  • Sofinnova Investments added most to AbbVie in Q2 2020, an estimated $17.8M increase.
  • Sofinnova Investments's biggest Q2 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.6M.
  • Sofinnova Investments fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $27.6M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.59B portfolio in Q2 2020.
  • Sofinnova Investments opened 29 new positions and closed 17 in Q2 2020.
  • Sofinnova Investments's portfolio value rose 47% quarter-over-quarter to $1.59B.

Based on Sofinnova Investments's 13F filing for Q2 2020, filed 13 Aug 2020.